Raul E Isturiz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9134209/publications.pdf

Version: 2024-02-01

23 686 13 22 g-index

23 23 23 23 863

23 23 23 863
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Review of Vaccines, 2017, 16, 1007-1027.	4.4	98
2	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clinical Infectious Diseases, 2018, 67, 1498-1506.	5.8	98
3	Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: AÂSystematic Review and Meta-analysis of Observational Studies. Clinical Infectious Diseases, 2019, 68, 2135-2143.	5.8	70
4	Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine, 2019, 37, 3352-3361.	3.8	54
5	Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. Vaccine, 2018, 36, 7479-7486.	3.8	52
6	Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. Vaccine, 2019, 37, 6310-6316.	3.8	43
7	Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009â€'2017. Journal of Infection, 2020, 81, 557-566.	3.3	33
8	Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults. Clinical Infectious Diseases, 2021, 73, 1216-1222.	5.8	33
9	Upper respiratory tract colonization with <i>Streptococcus pneumoniae</i> in adults. Expert Review of Vaccines, 2020, 19, 353-366.	4.4	31
10	Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States. Human Vaccines and Immunotherapeutics, 2019, 15, 841-849.	3.3	29
11	Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine. JAMA Network Open, 2022, 5, e221111.	5.9	26
12	US College Students Are at Increased Risk for Serogroup B Meningococcal Disease. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 244-247.	1.3	20
13	Diabetes mellitus as a vaccine-effect modifier: a review. Expert Review of Vaccines, 2020, 19, 445-453.	4.4	20
14	One-Year Quality of Life Post–Pneumonia Diagnosis in Japanese Adults. Clinical Infectious Diseases, 2021, 73, 283-290.	5.8	20
15	The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia. Expert Review of Vaccines, 2021, 20, 269-280.	4.4	15
16	The epidemiologic and biologic basis for classifying older age as a high-risk, immunocompromising condition for pneumococcal vaccine policy. Expert Review of Vaccines, 2021, 20, 691-705.	4.4	14
17	Concomitant administration of meningococcal vaccines with other vaccines in adolescents and adults: a review of available evidence. Human Vaccines and Immunotherapeutics, 2019, 15, 2205-2216.	3.3	9
18	Lessons from mass vaccination response to meningococcal B outbreaks at US universities. Postgraduate Medicine, 2020, 132, 614-623.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence. Human Vaccines and Immunotherapeutics, 2020, 16, 2758-2772.	3.3	7
20	2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults. Open Forum Infectious Diseases, 2019, 6, S953-S954.	0.9	3
21	Response to Mungall et al. letter to the editor on Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert review of vaccines 2017;16(10):1007–27. Expert Review of Vaccines, 2018, 17, 669-671.	4.4	2
22	Meningococcal vaccination: a discussion with all adolescents, whether college-bound or not. Postgraduate Medicine, 2019, 131, 551-554.	2.0	1
23	Response to Effectiveness of the 10-Valent Pneumococcal Nontypeable <i>Haemophilus influenzae</i> Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland. Journal of the Pediatric Infectious Diseases Society, 2017. 6. piw074.	1.3	o